Four different Kentucky lobbyists made more than $1 million for their efforts to influence policy and government over the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Analysts project ongoing solid performance from the CF business. BMO Capital Markets estimates Vertex will generate revenues of $11,573 million in 2025, with earnings per share reaching $18.05 ...

Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Chris Brown claims a 2024 documentary focused on the sexual-assault and -abuse allegations against him is defamatory. The singer is suing Warner Bros. Discovery for $500 million over Chris Brown ...

A rising star, Scott Eastwood is forging his own path with action-packed roles in Wrath of Man (2021), Dangerous (2021) and Fast X (2023). The son of Hollywood legend, Clint Eastwood, Scott may be ...

Chris Brown is taking legal action months after a documentary exploring his alleged history of violence was released. The singer-songwriter sued Warner Bros. Discovery and several others for their ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

This story has been updated with new information. Former ambassador and U.S. Sen. Scott Brown met with Republican leaders in Washington, D.C., Wednesday as he gears up for a potential run for U ...